Myelodysplastic Syndrome Excellence Forum

Conference Coverage

Analyzing Management and Treatment Options for Patients With High-Risk MDS

10/08/2024

At the 2024 SOHO meeting, Guillermo Garcia-Manero, MD, shared expert insight into treatment options for patients with high-risk myelodysplastic syndrome.

At the 2024 SOHO meeting,...

10/08/2024

Oncology

Conference Coverage

Examining Current and Upcoming Treatment Options for Patients With Low-Risk MDS

10/04/2024

Guillermo Garcia-Manero , MD;

At the 2024 SOHO meeting, Guillermo Garcia-Manero, MD, shared expert insight into treatment options that are available and upcoming for patients with low-risk myelodysplastic syndrome.

At the 2024 SOHO meeting,...

10/04/2024

Oncology

Videos

Examining Risk Stratification and Novel Treatment Options for Patients With Low and Intermediate-Risk MDS

07/28/2024

Pinkal Desai, MD, discusses risk stratification, restructured disease classifications, and current treatment options for patients with low and intermediate-risk myelodysplastic syndrome at the 2024 Great Debates & Updates meeting.

Pinkal Desai, MD, discusses risk...

07/28/2024

Oncology

Aditi Shastri, MD, Montefiore Einstein Comprehensive Cancer Center

Videos

How I Treat: An Elderly Patient With Lower-Risk, Ringed Sideroblastic Negative MDS

07/17/2024

Aditi Shastri, MD, discusses the treatment regimen she chose for an older patient with lower-risk, ringed sideroblastic negative myelodysplastic syndrome.

Aditi Shastri, MD, discusses the...

07/17/2024

Oncology

Areej El-Jawahri, MD, Massachusetts General Hospital

Conference Coverage

Palliative Care vs Standard of Care in Discussion of End-of-Life Care Preferences for Patients With AML and MDS

06/01/2024

Featuring Areej El-Jawahri, MD

Featuring Areej El-Jawahri, MD ...

Areej El-Jawahri MD, discusses trial results that showed palliative care significantly improved the rates of discussion and documentation of end-of-life care preferences, reduced hospitalization, and improved quality of life for patients with...

Areej El-Jawahri MD, discusses...

06/01/2024

Oncology

Conference Coverage

Recent Updates in Risk Stratification and Treatment Methods for Patients With MDS

04/10/2024

Featuring Aditi Shastri, MD

During the 2024 Great Debates & Updates in Hematological Malignancies Meeting, Aditi Shastri, MD, shares expert insight on recent updates in risk stratification and treatment regimens for patients with low to intermediate risk myelodysplastic...

During the 2024 Great Debates &...

04/10/2024

Oncology

Benjamin Tomlinson, MD, Seidman Cancer Center

Videos

How I Treat: A Patient With Myelodysplastic Syndrome With Isolated Deletion of 5q

02/29/2024

Benjamin Tomlinson , MD;

Benjamin Tomlinson, MD, explains the course of treatment he selected for a 49-year-old patient with myelodysplastic syndrome with isolated deletion of 5q.

Benjamin Tomlinson, MD, explains...

02/29/2024

Oncology

Videos

Luspatercept vs Epoetin Alfa for Anemia Therapy Among Patients With ESA-Naive, Transfusion-Dependent Lower-Risk MDS

10/10/2023

Guillermo Garcia-Manero , MD;

More patients achieved transfusion-independence and an increase in hemoglobin levels with luspatercept versus epoetin alfa, according to data presented at the SOHO 2023 annual meeting by Guillermo Garcia-Manero, MD.

More patients achieved...

10/10/2023

Oncology

Videos

New Developments in Risk Stratification and Management of High-Risk and Low-Risk MDS

08/19/2023

Amer Zeidan , MBBS;

At the 2023 Great Debates & Updates in Hematologic Malignancies Meeting, Amer Zeidan, MBBS, speaks on recent developments in risk stratification and treatment management among patients with high-risk and low-risk myelodysplastic syndromes.

At the 2023 Great Debates &...

08/19/2023

Oncology

Videos

Effective Risk Stratification for Patients With Myelodysplastic Syndromes

04/26/2023

At the 2023 Great Debates & Updates in Hematologic Malignancies conference in New York, New York, Amer Zeidan, MBBS, MHS, discussed effective risk stratification among patients with myelodysplastic syndromes.

At the 2023 Great Debates &...

04/26/2023

Oncology

Recent News

News

Osimertinib Lacks Activity in Neoadjuvant Setting for Early-Stage Non-Small Cell Lung Cancer With EGFR Mutation

08/08/2024

Stephanie Holland ;

Results from a phase 2 study demonstrated that neoadjuvant osimertinib did not improve the major pathological response rate among patients with early-stage non-small cell lung cancer harboring an EGFR mutation.

Results from a phase 2 study...

08/08/2024

Oncology

FDA Approval

FDA Approves Denileukin Diftitox for Patients With R/R Cutaneous T-Cell Lymphoma

08/08/2024

Amber Denham ;

The US Food and Drug Administration approved novel immunotherapy denileukin diftitox-cxdl for the treatment of patients with relapsed/refractory cutaneous T-cell lymphoma after at least 1 prior systemic therapy.

The US Food and Drug...

08/08/2024

Oncology

News

Tailored Dose-Dense Chemotherapy Improved Survival Outcomes Among Patients With High-Risk Early Breast Cancer

08/07/2024

Stephanie Holland ;

According to results from the phase 3 PANTHER trial, tailored and dose-dense chemotherapy in the adjuvant setting improved survival outcomes compared to standard chemotherapy among patients with high-risk early breast cancer.

According to results from the...

08/07/2024

Oncology

News

Frontline Treatment Management for Patients With FL Reduces Risk of High-Grade Transformation to DLBCL

08/07/2024

Amber Denham ;

A recent study demonstrated that frontline treatment management reduced the risk of high-grade transformation to diffuse large B-cell lymphoma among patients with follicular lymphoma, but not among patients with marginal zone lymphoma.

A recent study demonstrated that...

08/07/2024

Oncology

News

Optimal Sotorasib Dose for Patients With KRAS G12C-Mutated Advanced Non-Small Cell Lung Cancer

08/07/2024

Stephanie Holland ;

Results from a phase 2 study found that 960 mg of sotorasib is preferable to 240 mg among patients with previously treated KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer.

Results from a phase 2 study...

08/07/2024

Oncology

FDA Approval

FDA Approves Vorasidenib for Patients With IDH1/IDH2-Mutated Grade 2 Astrocytoma or Oligodendroglioma

08/06/2024

Stephanie Holland ;

Based on results from the INDIGO trial, the FDA has approved vorasidenib for adult and pediatric patients 12 years and older with grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation following surgery.

Based on results from the INDIGO...

08/06/2024

Oncology

FDA Approval

FDA Approves Afamitresgene Autoleucel for Certain Unresectable or Metastatic Synovial Sarcoma

08/02/2024

Allison Casey ;

On August 2, 2024, the US Food and Drug Administration (FDA) granted accelerated approval to afamitresgene autoleucel for the treatment of adult patients with certain unresectable or metastatic synovial sarcomas who had received prior...

On August 2, 2024, the US Food...

08/02/2024

Oncology

FDA Approval

FDA Approves Dostarlimab Plus Chemotherapy for Patients With Primary Advanced or Recurrent Endometrial Cancer

08/01/2024

Allison Casey ;

The FDA approved dostarlimab plus carboplatin and paclitaxel, followed by single-agent dostarlimab for patients with primary advanced or recurrent endometrial cancer.

The FDA approved dostarlimab...

08/01/2024

Oncology

News

Iadademstat and Azacitidine Combination Therapy Demonstrates Manageable Safety, Promising Efficacy for Patients With Newly Diagnosed AML

08/01/2024

Amber Denham ;

The first-line combination of iadademstat and azacitidine demonstrates a manageable safety profile and promising results among patients with acute myeloid leukemia, according to phase 2 results from the ALICE trial.

The first-line combination of...

08/01/2024

Oncology

News

Effect of Food on Selumetinib Dosing for Adolescent Patients With Neurofibromatosis Type 1 With Plexiform Neurofibromas

08/01/2024

Allison Casey ;

In the phase 1 trial, the addition of a low-fat meal with doses of selumetinib did not significantly impact selumetinib exposure or gastrointestinal toxicities among adolescent patients with neurofibromatosis type 1 with plexiform...

In the phase 1 trial, the...

08/01/2024

Oncology